Alan Geller is listed as a director on 2 SEC Form D filings by 1 issuer in Aug 2015: Turing Pharmaceuticals AG (Baar, Switzerland (as filed: V8) — pharmaceuticals — 2015; $90.3M reported sold to 43 investors).
What this means One deal on file with the SEC, filed Aug 2015. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Martin Shkreli (2 shared filings), Michael Harrison (2 shared filings), Ron Tilles (2 shared filings), Walter Blum (2 shared filings) and Howard Dorfman (1 shared filing).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Alan. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 4 bankruptcy cases matching the name listed in Key records below.
What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 2 public filings for Alan Geller and found 5 differences, 3 worth asking the sponsor about: Regulator action naming a team member: Martin Shkreli, et al. (Feb 28, 2022); Regulator action naming a team member: Martin Shkreli, et al. (Apr 6, 2021); and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.